Background: Deficiency of adenosine deaminase 2 (DADA2) is an autoinflammatory disease caused by deleterious ADA2 variants. The frequency of these variants in the general population, and hence the expected disease prevalence, remain unknown.
Objective: We aimed to characterize the functional impact and carrier frequency of ADA2 variants.
Methods: We performed functional studies and in silico analysis on 163 ADA2 variants, including DADA2-associated variants and population variants identified in the Genome Aggregation Database. We estimated the carrier rate using the aggregate frequency of deleterious variants.
Results: Functional studies of ADA2 variants revealed that 77 (91%) of 85 of DADA2-associated variants reduced ADA2 enzymatic function by >75%. Analysis of 100 ADA2 variants in the database showed a full spectrum of impact on ADA2 function, rather than a dichotomy of benign versus deleterious variants. We found several in silico algorithms that effectively predicted the impact of ADA2 variants with high sensitivity and specificity, and confirmed a correlation between the residual function of ADA2 variants in vitro and the plasma ADA2 activity of individuals carrying these variants (n = 45; r = 0.649; P < .0001). Using <25% residual enzymatic activity as the cutoff to define potential pathogenicity, integration of our results with the database population data revealed an estimated carrier frequency of at least 1 in 236 individuals, corresponding to an expected DADA2 disease prevalence of ~1 in 222,000 individuals.
Conclusions: Functional annotation guides the interpretation of ADA2 variants to create a framework that enables estimation of DADA2 carrier frequency and disease prevalence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591146 | PMC |
| http://dx.doi.org/10.1016/j.jaci.2021.04.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dominant negative mutations cause ADA2 deficiency in heterozygous carriers.
medRxiv
December 2024
Laboratory Inborn errors of Immunity, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Human ADA2 deficiency (DADA2) is an inborn error of immunity with a broad clinical phenotype which encompasses vasculopathy including livedo racemosa and lacunar strokes, as well as hemato-immunological features. Diagnosis is based on the combination of decreased serum ADA2 activity and the identification of biallelic deleterious alleles in the gene. DADA2 carriers harbor a single pathogenic variant in and are mostly considered healthy and asymptomatic.
View Article and Find Full Text PDFCarrier frequency and incidence estimation of deficiency of adenosine deaminase 2 in the Chinese population based on massive exome sequencing data.
Clin Immunol
December 2024
The Central Laboratory of Birth Defects Prevention and Control, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, China; Ningbo Key Laboratory for the Prevention and Treatment of Embryogenic Diseases, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, China; Ningbo Key Laboratory of Genomic Medicine and Birth Defects Prevention, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, China. Electronic address:
Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disease characterised by early onset stroke, recurrent fever, and diverse vascular pathologies, caused by loss-of-function homozygous or compound heterozygous variants of ADA2. This research aimed to determine the carrier frequency and expected incidence of DADA2 in China, using massive exome sequencing (ES) data. A total of 50 likely pathogenic/pathogenic variants (LP/PVs) were identified among 69,413 Chinese individuals, including 20 novel and rare variants (<0.
View Article and Find Full Text PDFDeficiency of Adenosine Deaminase 2.
Turk J Haematol
August 2024
Hacettepe University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Türkiye
Article Synopsis
- Adenosine deaminase 2 deficiency is an inherited autoinflammatory disorder caused by mutations leading to an inflammatory response, characterized by high levels of inflammatory cytokines and issues with neutrophil function.
- The condition presents a wide range of symptoms beyond vasculitis, including hematological and immunological issues, requiring diagnosis through genetic testing and measurement of enzyme activity.
- Current treatments focus on TNF-α inhibitors for controlling vasculitis, while severe cases may benefit from stem cell transplants; future therapies may include recombinant protein and gene therapy.
Genetic Testing in Patients with Autoimmune Lymphoproliferative Syndrome: Experience of 802 Patients at Cincinnati Children's Hospital Medical Center.
J Clin Immunol
July 2024
Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Article Synopsis
- Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder characterized by symptoms like swollen lymph nodes, spleen enlargement, low blood cell counts, and a higher risk of lymphoma, making diagnosis difficult, especially when mixed with similar immune deficiencies.
- A study at Cincinnati Children's Hospital evaluated a 15-gene next-generation sequencing (NGS) panel on 802 patients, revealing that 62 (7.7%) had a confirmed ALPS diagnosis, predominantly due to mutations in the FAS gene, and the diagnostic yield increased to 30% with certain immunological findings.
- The research identified novel genetic variants, showed the importance of family studies for managing at-risk relatives, and demonstrated that the ALPS
A pilot study of childhood-onset Takayasu arteritis using whole exome sequencing suggests oligogenic inheritance involving classical complement, collagen, and autoinflammatory pathways.
Clin Rheumatol
August 2024
Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, Tamil Nadu, India.
Takayasu arteritis (TA) is a chronic granulomatous inflammatory disease affecting the aorta and its branches. Paediatric TA (pTA) may present from 6 months after birth till the adolescent age group. Genetics and pathogenesis of pTA are not fully understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!